期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Awake thoracoscopic surgery under epidural anesthesia: is it really safe? 被引量:2
1
作者 ryoichi nakanishi Manabu Yasuda 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2014年第4期368-370,共3页
Thoracoscopic surgeries usually require single-lung ventilation under general anesthesia because of the need to obtain a sufficient working space.In patients with impaired pulmonary function,if the patient can undergo... Thoracoscopic surgeries usually require single-lung ventilation under general anesthesia because of the need to obtain a sufficient working space.In patients with impaired pulmonary function,if the patient can undergo general anesthesia,a more selected collapse of the lung is considered to be beneficial for intraoperative oxygenation.The selective bronchial blockade of the lobe to be 展开更多
关键词 硬膜外麻醉 手术 腔镜 安全 全身麻醉 肺功能 患者 支气管
下载PDF
Phase Ⅱ trial of carboplatin/docetaxel in patients with resected NSCLC
2
作者 Hidetaka Uramoto ryoichi nakanishi +6 位作者 Akihiko Uchiyama Masaaki Inoue Masakazu Sugaya Teruo Iwata Noriyuki Ebi Takeshi Hanagiri Fumihiro Tanaka 《World Journal of Respirology》 2014年第1期1-7,共7页
AIM: To investigate the development of a safer chemotherapeutic regimen with better compliance, a total of 67 patients were enrolled as a single arm in a twostage multi-center phase Ⅱ study.METHODS: The patients rece... AIM: To investigate the development of a safer chemotherapeutic regimen with better compliance, a total of 67 patients were enrolled as a single arm in a twostage multi-center phase Ⅱ study.METHODS: The patients received chemotherapy with carboplatin(CBDCA) with an area under the curve(AUC) of 5, and docetaxel(DTX) at 60 mg/m2 tri-weekly for three cycles after surgery. The primary endpoint of this study was compliance, while the secondary endpoints were the adverse events(AE) and recurrencefree survival(RFS).RESULTS: Sixty-one patients were treated in this study arm. The patients were 43 males and 18 females, with a median age of 64.6 years. Fifty-one patients(83.6%)completed all three cycles of therapy. The presence of Grade 3 and 4 neutropenia was noted in 25% and 66%of the patients, respectively. The non-hematological AE were less frequently reported, and no treatmentrelated death was registered. The two-year RFS and OS rates of the 61 patients were 69.8% and 88.3%,respectively.CONCLUSION: A tri-weekly schedule of CBDCA and DTX as adjuvant chemotherapy showed a favorable feasibility. 展开更多
关键词 NON-SMALL cell lung cancer ADJUVANT chemotherapy CARBOPLATIN DOCETAXEL Treatment COMPLIANCE Surgical RESECTION
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部